BRENTWOOD, Tenn. / Sep 30, 2024 / Business Wire / Ardent Health (NYSE: ARDT) has been added as a member of the broad-market Russell 3000® Index and Russell 2000®, effective Monday, September 23, 2024, as part of the quarterly U.S. Russell Index Initial Public Offering (IPO) update.
“We are pleased to join the Russell 3000® Index and look forward to building awareness around the Ardent growth story while increasing our exposure to new investor audiences,” said Ardent President and Chief Executive Officer Marty Bonick. “Ardent Health’s inclusion is an important milestone and underscores our strategic focus on delivering sustainable growth and value as we build a consumer-focused ecosystem of care in the communities we serve.”
Membership in the U.S. all-cap Russell 3000® Index, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index as well as the appropriate growth and value style indexes. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $9 trillion in assets are benchmarked against Russell’s U.S. indexes. Russell indexes are part of FTSE Russell, a leading global index provider.
For more information on the Russell 2000® and 3000® Indexes and the Russell indexes quarterly updates for IPOs, go to https://www.lseg.com/en/ftse-russell/russell-reconstitution/ipo-additions.
About Ardent Health
Ardent Health (NYSE: ARDT) is a leading provider of healthcare in growing mid-sized urban communities across the U.S. With a focus on people and investments in innovative services and technologies, Ardent is passionate about making healthcare better and easier to access. Through its subsidiaries, the Company delivers care through a system of 30 acute care hospitals and more than 200 sites of care with over 1,700 affiliated providers across six states. For more information, please visit www.ardenthealth.com.
Last Trade: | US$12.42 |
Daily Change: | 0.64 5.43 |
Daily Volume: | 533,843 |
Market Cap: | US$1.770B |
March 31, 2025 February 26, 2025 November 06, 2024 |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load